Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | ERN1 | O75460 | 2/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | ALDH5A1 | P51649 | 3/20 | 0.42 |
| ▸ | ABAT | P80404 | 3/20 | 0.42 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.42 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | UNG | P13051 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29957506 | 1.00 | CTDSP1 (0.53) | CTDSP1RAB9AKDM4EPTGS2CYP1A2 | |
| SCHEMBL9098185 | 0.85 | PLAU (0.53) | RAB9AKDM4EPTGS2CYP1A2GRIN2D | |
| SCHEMBL11963906 | 0.81 | CTDSP1 (0.53) | CTDSP1KDM4ECYP1A2ERN1GRIN2D | |
| SCHEMBL9883875 | 0.78 | KIF11 (0.42) | RAB9AKDM4EPTGS2ERN1ALDH1A1 | |
| SCHEMBL15625133 | 0.78 | CD74 (0.55) | CTDSP1RAB9AKDM4EPTGS2CYP1A2 | |
| SCHEMBL17988341 | 0.78 | KDM4E (0.59) | CTDSP1KDM4ECYP1A2GRIN2DGRIN2A | |
| SCHEMBL5617799 | 0.78 | ALDH1A1 (0.56) | RAB9AKDM4ECYP1A2ERN1ALDH1A1 | |
| SCHEMBL3257311 | 0.77 | CYP2A6 (0.57) | RAB9ACYP1A2ALDH1A1TRIM24HPGD | |
| SCHEMBL4102305 | 0.77 | ALDH1A1 (0.50) | RAB9AKDM4EPTGS2CYP1A2ALDH1A1 | |
| SCHEMBL5381553 | 0.77 | PTGER4 (0.50) | RAB9AKDM4EPTGS2ERN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3929207-B1 | PEPTIDE FTTFTVT FOR USE IN TREATING FIBROSIS | UNIV TEXAS (US) | 2024-07-17 | — | — | EP | claimed |
| EP-3929207-A1 | INHIBITION OF PULMONARY FIBROSIS WITH NUTLIN-3A AND PEPTIDES | Board of Regents, The University of Texas System (US) | 2021-12-29 | — | — | EP | claimed |
| US-20180086791-A1 | INHIBITION OF PULMONARY FIBROSIS WITH NUTLIN-3A AND PEPTIDES | UNIV TEXAS (US) | 2018-03-29 | — | — | US | claimed |
| WO-2025033019-A1 | COMPOUND, COMPOSITION, METHOD FOR EXPRESSING SENSITIZING EFFECT, AND PRODUCTION METHOD | 三菱瓦斯化学株式会社 | 2025-02-13 | — | — | WO | disclosed |
| WO-2024214321-A1 | COMPOUND, COMPOSITION, METHOD FOR EXPRESSING SENSITIZING EFFECT, AND METHOD FOR PRODUCING SAME | 三菱瓦斯化学株式会社 | 2024-10-17 | — | — | WO | disclosed |
| EP-3929207-B1 | PEPTIDE FTTFTVT FOR USE IN TREATING FIBROSIS | UNIV TEXAS (US) | 2024-07-17 | — | — | EP | disclosed |
| US-20240067713-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CHRONIC LUNG DISEASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240059736-A1 | INHIBITION OF PULMONARY FIBROSIS WITH NUTLIN-3A AND PEPTIDES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-02-22 | — | — | US | disclosed |
| US-11905336-B2 | Modified peptide fragments of CAV-1 protein and the use thereof in the treatment of fibrosis | LUNG THERAPEUTICS, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20240018186-A1 | MODIFIED PEPTIDE FRAGMENTS OF CAV-1 PROTEIN AND THE USE THEREOF IN THE TREATMENT OF FIBROSIS | LUNG THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2024015857-A2 | MODIFIED CAVEOLIN-1 PEPTIDE FORMULATIONS AND METHODS OF MANUFACTURING AND USE THEREOF | LUNG THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2002064621-A2 | HISTIDINE PROLINE RICH GLYCOPROTEIN (HPRG) AS AN ANTI-ANGIOGENIC AND ANTI-TUMOR AGENT | ATTENUON, LLC (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002014369-A2 | HUMAN KININOGEN D5 DOMAIN POLYPEPTIDES AND THEIR USE | ATTENUON, LLC (US) | 2002-02-21 | — | — | WO | disclosed |
| WO-2001098343-A2 | CONSERVED DIAPHANOUS-RELATED FORMIN AUTOREGULATORY DOMAIN (DAD) | VAN ANDEL INSTITUTE (US) | 2001-12-27 | — | — | WO | disclosed |
| US-5994309-A | OCTAPEPTIDE; ANTITUMOR AGENT | ANGSTROM PHARMACEUTICALS, INC. (US) | 1999-11-30 | — | — | US | disclosed |
| EP-0950096-A1 | ANTI-INVASIVE AND ANTI-ANGIOGENIC UROKINASE FRAGMENTS AND THEIR USE | Angstrom Pharmaceuticals, inc. (US) | 1999-10-20 | — | — | EP | disclosed |
| WO-1999005263-A1 | ANTI-INVASIVE AND ANTI-ANGIOGENIC UROKINASE FRAGMENTS AND THEIR USE | ANGSTROM PHARMACEUTICALS, INC. (US) | 1999-02-04 | — | — | WO | disclosed |
| EP-0254578-B1 | ANTIBIOTIC INTERMEDIATES | ELI LILLY AND COMPANY (US) | 1993-09-08 | — | — | EP | disclosed |
| US-4772694-A | Chiral 3-(1,2,5-trisubstituted imidazolidinone) azetidinone antibiotic intermediates | ELI LILLY AND COMPANY (US) | 1988-09-20 | — | — | US | disclosed |
| EP-0254578-A1 | Antibiotic intermediates | ELI LILLY AND COMPANY (US) | 1988-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086791-A1 | INHIBITION OF PULMONARY FIBROSIS WITH NUTLIN-3A AND PEPTIDES | IGFBP4, FN1, MDM2 | CTDSP1 681/4885RAB9A 3391/4885KDM4E 1941/4885 |
| US-20240059736-A1 | INHIBITION OF PULMONARY FIBROSIS WITH NUTLIN-3A AND PEPTIDES | IGFBP4, FN1, MDM2 | CTDSP1 681/4885RAB9A 3391/4885KDM4E 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.